Contineum Therapeutics third quarter 2026 net loss widens to $18.7M with cash runway through 2029

Contineum Therapeutics reported a third quarter 2026 net loss of $18.7 million, or $0.49 per share, as the clinical-stage company ramped up R&D spending for its lead pulmonary fibrosis program. The company maintained a strong liquidity position with $244.5 million in cash and marketable securities, providing a capital runway into mid-2029.

Key Highlights

• Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by scaling the PIPE-791 Phase 2 clinical program.
• The company activated over 100 clinical sites across 16 countries to support enrollment for the PROPEL-IPF trial, which is evaluating its LPAR1 antagonist.
• Management expects current cash resources to sustain operations for approximately three years, extending one year beyond the projected completion of the idiopathic pulmonary fibrosis trial.